Reuters logo
BRIEF-Cerenis Therapeutics announces positive results from CER-209 phase I single dose tolerance study for NAFLD and NASH
June 7, 2017 / 5:25 PM / 5 months ago

BRIEF-Cerenis Therapeutics announces positive results from CER-209 phase I single dose tolerance study for NAFLD and NASH

June 7 (Reuters) - CERENIS THERAPEUTICS HOLDING SA:

* CERENIS THERAPEUTICS: POSITIVE RESULTS FROM THE CER-209 PHASE I SINGLE DOSE TOLERANCE STUDY FOR NAFLD AND NASH

* COMPLETION OF SINGLE DOSE TOLERANCE STUDY (SDT) FOR CER-209

* NO DRUG RELATED SAFETY NOR TOLERANCE ISSUES IDENTIFIED

* MULTIPLE DOSE TOLERANCE STUDY (MDT) NOW READY TO PROCEED

* PHARMACOKINETICS OBSERVATIONS SUPPORT CER-209 ONCE DAILY ORAL DOSING Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below